1. Home
  2. AKRO vs FBNC Comparison

AKRO vs FBNC Comparison

Compare AKRO & FBNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • FBNC
  • Stock Information
  • Founded
  • AKRO 2017
  • FBNC 1934
  • Country
  • AKRO United States
  • FBNC United States
  • Employees
  • AKRO N/A
  • FBNC N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • FBNC Major Banks
  • Sector
  • AKRO Health Care
  • FBNC Finance
  • Exchange
  • AKRO Nasdaq
  • FBNC Nasdaq
  • Market Cap
  • AKRO 2.2B
  • FBNC 1.7B
  • IPO Year
  • AKRO 2019
  • FBNC N/A
  • Fundamental
  • Price
  • AKRO $29.53
  • FBNC $46.82
  • Analyst Decision
  • AKRO Strong Buy
  • FBNC Buy
  • Analyst Count
  • AKRO 8
  • FBNC 1
  • Target Price
  • AKRO $46.83
  • FBNC $56.00
  • AVG Volume (30 Days)
  • AKRO 535.2K
  • FBNC 192.8K
  • Earning Date
  • AKRO 11-08-2024
  • FBNC 01-22-2025
  • Dividend Yield
  • AKRO N/A
  • FBNC 1.85%
  • EPS Growth
  • AKRO N/A
  • FBNC N/A
  • EPS
  • AKRO N/A
  • FBNC 2.48
  • Revenue
  • AKRO N/A
  • FBNC $362,644,000.00
  • Revenue This Year
  • AKRO N/A
  • FBNC N/A
  • Revenue Next Year
  • AKRO N/A
  • FBNC $9.87
  • P/E Ratio
  • AKRO N/A
  • FBNC $19.10
  • Revenue Growth
  • AKRO N/A
  • FBNC N/A
  • 52 Week Low
  • AKRO $15.32
  • FBNC $29.53
  • 52 Week High
  • AKRO $37.00
  • FBNC $50.34
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 46.87
  • FBNC 54.75
  • Support Level
  • AKRO $28.45
  • FBNC $47.06
  • Resistance Level
  • AKRO $31.41
  • FBNC $48.18
  • Average True Range (ATR)
  • AKRO 1.29
  • FBNC 0.99
  • MACD
  • AKRO -0.15
  • FBNC -0.20
  • Stochastic Oscillator
  • AKRO 37.64
  • FBNC 39.88

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

About FBNC First Bancorp

First Bancorp is a bank holding company. The company is engaged in providing commercial and consumer banking services, mortgage lending, SBA lending, accounts receivable financing, and investment advisory services.

Share on Social Networks: